. Author manuscript; available in PMC: 2022 Jul 25.

Published in final edited form as: Eur Urol Oncol. 2020 Oct 21;4(2):227–234. doi: 10.1016/j.euo.2020.09.004

Table 2 –

Baseline clinical characteristics at the time of first mpMRI.

Clinical characteristics, median (IQR)

Age (yr)	63 (58–68)
PSA (ng/mL)	5.38 (3.95–7.87)
Prostate volume (mL)	51 (38–72)
PSAD (ng/mL²)	0.10 (0.07–0.14)
No. of lesions	2 (1–3)
Index lesion diameter (mm)	10 (7–14)
NIH suspicion score, N (%)
No lesion	19 (4.9)
Low	53 (13.5)
Low-moderate	22 (5.6)
Moderate	244 (62.4)
Moderate-high	22 (5.6)
High	19 (4.9)
NA	12 (3.1)
PI-RADS classification, N (%)
1	9 (2.3)
2	13 (3.3)
3	25 (6.4)
4	74 (18.9)
5	21 (5.4)
NA	249 (63.7)
Gleason grade group, N (%)
1	287 (73.4)
2	104 (26.6)

IQR = interquartile range; mpMRI = multiparametric magnetic resonance imaging; NA = not applicable; PI-RADS = Prostate Imaging Reporting and Data System; PSA = prostate-specific antigen; PSAD = prostate-specific antigen density.